Cargando…

A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?

The safety, inherent immunogenicity, stability, and low-cost production of bacteriophages make them an ideal platform for vaccine development. Most vaccination strategies against COVID-19 have targeted the spike protein of SARS-CoV-2 to generate neutralizing antibodies. P1, a truncated RBD-derived s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salehi, Zahra, Rasaee, Mohammad Javad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144462/ https://www.ncbi.nlm.nih.gov/pubmed/37112745 http://dx.doi.org/10.3390/vaccines11040833

Ejemplares similares

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
por: Noorabad Ghahroodi, Faezeh, et al.
Publicado: (2022)

Recombinant highly antigenic truncated fusion-based protein as a diagnostic antigen for anti-SARS-CoV-2 nucleocapsid antibody ELISA
por: Salarifar, Abbasali, et al.
Publicado: (2023)

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
por: Sun, Yi-Sheng, et al.
Publicado: (2021)

Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates
por: Mendoza-Ramírez, Noe Juvenal, et al.
Publicado: (2023)

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
por: Ghaemi, Amir, et al.
Publicado: (2022)

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
por: Gerez, Guillaume, et al.
Publicado: (2022)

Enhanced hyluronic acid production in Streptococcus zooepidemicus by over expressing HasA and molecular weight control with Niscin and glucose
por: Zakeri, Alireza, et al.
Publicado: (2017)

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
por: Leal, Lorna, et al.
Publicado: (2023)

Phage based vaccine: A novel strategy in prevention and treatment
por: Mohammad Hasani, Sharareh, et al.
Publicado: (2023)

Development of Sensitive and Rapid RNA Transcription-based Isothermal Amplification Method for Detection of Mycobacterium tuberculosis
por: Ramezani, Reihaneh, et al.
Publicado: (2019)

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
por: Du, Yingying, et al.
Publicado: (2021)

The effect of capsulated and noncapsulated egg-yolk–specific antibody to reduce colonization in the intestine of Salmonella enterica ssp. enterica serovar Infantis–challenged broiler chickens
por: Hatamzade Isfahani, Nasim, et al.
Publicado: (2020)

Design of an engineered ACE2 as a novel therapeutics against COVID-19
por: Payandeh, Zahra, et al.
Publicado: (2020)

Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein
por: Pouriayevali, Mohammad Hassan, et al.
Publicado: (2022)

Recombinant expression of SARS-CoV-2 receptor binding domain (RBD) in Escherichia coli and its immunogenicity in mice
por: Rahbar, Zahra, et al.
Publicado: (2022)

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
por: Barreiro, Antonio, et al.
Publicado: (2023)

Corrigendum to “Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein” [Vaccine 40(20) (2022) 2856–2868]
por: Pouriayevali, Mohammad Hassan, et al.
Publicado: (2022)

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
por: Sun, Shihui, et al.
Publicado: (2021)

Detection of TNT-derivatives with recombinant phages
por: Simonovicá, Mladen, et al.
Publicado: (2012)

A lab‐on‐a‐chip model of glaucoma
por: Nafian, Fatemeh, et al.
Publicado: (2020)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

The effect of exercise mode and intensity of sub-maximal physical activities on salivary testosterone to cortisol ratio and α-amylase in young active males
por: AZARBAYJANI, MOHAMMAD ALI, et al.
Publicado: (2011)

Mutated trimeric RBD vaccines: a platform against variants of concern
por: Aparicio, Belén, et al.
Publicado: (2023)

Expression, purification, and study on the efficiency of a new potent recombinant scFv antibody against the SARS-CoV-2 spike RBD in E. coli BL21
por: Yaghoobizadeh, Fatemeh, et al.
Publicado: (2023)

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
por: Lei, Hong, et al.
Publicado: (2022)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

Sodium oxybate—a new horizon for symptomatic treatment of RBD?
por: Stefani, Ambra, et al.
Publicado: (2023)

Development of in House ELISAs to Detect Antibodies to SARS-CoV-2 in Infected and Vaccinated Humans by Using Recombinant S, S1 and RBD Proteins
por: Yilmaz, Aysun, et al.
Publicado: (2022)

RECOMBINATIONS OF MUTANT PHAGES OF BACILLUS MEGATHERIUM 899A
por: Murphy, James S.
Publicado: (1953)

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
por: Pérez-Rodríguez, Sonia, et al.
Publicado: (2022)

Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19
por: Núñez-Muñoz, Leandro, et al.
Publicado: (2021)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Vaccination With Recombinant Filamentous fd Phages Against Parasite Infection Requires TLR9 Expression
por: Gomes-Neto, João F., et al.
Publicado: (2018)

Reduced Intracortical Facilitation to TMS in Both Isolated REM Sleep Behavior Disorder (RBD) and Early Parkinson’s Disease with RBD
por: Lanza, Giuseppe, et al.
Publicado: (2022)

Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2022)

Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice
por: Borgoyakova, Mariya B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0821srdsr8gk7c4488574d1kqf